Web: ?c=930d6c14fe03e2bad7a08c0d48846716" target="_blank" rel="nofollow"> Novartis external link
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
?c=930d6c14fe03e2bad7a08c0d48846716" target="_blank" rel="nofollow"> #display_name

Medicine Mar 12
Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) -   Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN -   Shannon Klinger named Chief Ethics, Risk and Compliance Officer, appointed to the ECN -   André Wyss, President Novartis Operations and Country President for Switzerl
Medicine Mar 7

Novartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model -   Agreement builds on our long-standing investment in and

Business Mar 2

Shareholders approve 21 st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow -   Dr.

Medicine Feb 22

Ultibro Breezhaler provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo   -   CLAIM is the first study to investigate the ef

Medicine Feb 16

Majority of patients with scalp psoriasis on Cosentyx (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life -   Scalp psoriasis affects 60 million people world

Medicine Mar 6

Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU) , is the only therapy recommended by the guideline for patients unresponsive to antihistami

Medicine Mar 1

Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis -   Collaboration combines Novartis' leadershi

Medicine Feb 16

Two thirds of patients on Cosentyx (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows -   Findings show absolute PASI <=1/<=2/<=3

Medicine Feb 14

Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis -   Cryptosporidiosis is the sec

website preview


Medicine and Life Sciences